Doctors are raising alarms about long-term antacid use because a growing body of evidence links proton pump inhibitors — medications like omeprazole, lansoprazole, and esomeprazole — to kidney disease, bone fractures, nutrient deficiencies, and potentially even dementia. These drugs were designed for short-term relief of acid reflux and GERD, yet up to one in five older adults now takes them continuously, often for years, without a clear ongoing medical reason. The FDA itself advises that over-the-counter PPIs be limited to a 14-day course, no more than three times per year. The gap between that recommendation and actual prescribing patterns is what has the medical community concerned.
Consider a common scenario: a 68-year-old is prescribed omeprazole during a hospital stay for stress ulcer prevention. After discharge, nobody reviews whether the medication is still needed, and the patient continues refilling the prescription for years. One study found that 81 percent of patients started on PPIs in acute care continued receiving them after transfer, though only 29 percent had appropriate indications. This kind of prescribing inertia is a major driver of the problem. In the sections ahead, we will examine the specific risks that have emerged from recent research — including the contested link to dementia — what the FDA has formally warned about, and what steps patients and caregivers can take to reassess whether these medications are still necessary.
Table of Contents
- What Exactly Are Doctors Worried About With Long-Term Antacid Use?
- The Silent Threat to Kidney Function
- The Dementia Question — What the Evidence Actually Shows
- Bone Fractures, Nutrient Deficiencies, and Infection Risk — The FDA’s Formal Warnings
- Why Stopping PPIs Is Harder Than It Sounds
- The ICU-to-Medicine-Cabinet Pipeline
- Where the Evidence Is Heading
- Conclusion
- Frequently Asked Questions
What Exactly Are Doctors Worried About With Long-Term Antacid Use?
The concern is not that PPIs are dangerous medications in themselves. They are effective at reducing stomach acid and can be genuinely necessary for conditions like Barrett’s esophagus, severe erosive esophagitis, or Zollinger-Ellison syndrome. The concern is one of scale and duration. Roughly 10 percent of American adults take PPIs, generating approximately 113 million prescriptions globally each year and an estimated $11 billion in annual spending in the United States alone. Many of these prescriptions run far longer than clinical guidelines recommend, and the cumulative risks of years-long use are only now becoming clear. The American Gastroenterological Association and the American College of Gastroenterology issued joint recommendations in 2022 stating that all PPI users should have their indication reviewed.
Patients without a clear ongoing reason for the medication should be offered a trial of deprescribing — a structured attempt to taper and stop the drug. this is not a fringe position. It reflects a consensus that the reflex to prescribe PPIs, and then never revisit that decision, has created a public health issue. The sheer volume of concerning signals across kidney function, bone density, infection risk, and cognitive health has prompted calls for what researchers describe as better prescribing stewardship. Compared to older antacid classes like H2 blockers (famotidine, for example), PPIs suppress acid far more aggressively and for a longer duration. That potency is precisely what makes them effective for serious acid-related conditions — and precisely what raises the stakes when they are used casually for mild heartburn that might respond to lifestyle changes or less potent alternatives.
The Silent Threat to Kidney Function
One of the most troubling findings involves the kidneys. PPI users face a 50 percent higher risk of chronic kidney disease and a 35 percent elevated risk of end-stage renal disease, according to research published in recent systematic reviews. What makes this particularly dangerous is that kidney damage from PPIs can develop without any obvious warning signs. More than half of patients who develop chronic kidney damage while taking PPIs experience no acute kidney problems beforehand. There is no dramatic moment of crisis — kidney function may silently deteriorate over months or years. This is a critical distinction for older adults, who already face age-related declines in kidney function.
A person taking omeprazole for persistent heartburn may have no idea their kidneys are being affected until routine bloodwork reveals elevated creatinine levels or reduced glomerular filtration rate. By that point, some degree of damage may be irreversible. For caregivers of people with dementia or other cognitive conditions, this is especially relevant. The person taking the PPI may not be tracking their own symptoms or lab results, making it easy for kidney decline to go unnoticed. However, if a patient has a confirmed diagnosis of severe GERD with esophageal erosion, the risk of stopping PPIs — including esophageal stricture or Barrett’s progression — may genuinely outweigh the kidney risk. This is not a blanket call to stop all PPIs. It is a call to weigh the tradeoffs with a physician, something that too often does not happen.
The Dementia Question — What the Evidence Actually Shows
For readers of a brain health website, the potential link between PPIs and dementia is understandably the most alarming finding. A study published in the journal Neurology found that people aged 45 and older who took PPIs for more than four years had a 33 percent higher risk of dementia compared to non-users. A German study of adults aged 75 and older reported a hazard ratio of 1.44 for Alzheimer’s disease specifically. Data from the UK Biobank found the dementia incidence rate among PPI users was roughly double that of non-users — 1.06 per 1,000 person-years versus 0.51. Those numbers sound stark. But there is an important counterpoint.
The ASPREE randomized trial — a higher-quality study design than the observational studies cited above — found no association between baseline PPI use and dementia risk, with a hazard ratio of 0.88. Most high-quality evidence currently finds no statistically significant causal link. The association observed in observational studies may be driven by confounding factors: people who take PPIs long-term tend to be older, sicker, and on more medications, all of which independently raise dementia risk. Researchers emphasize that these observational findings show association, not causation. That said, the volume and consistency of the signal across multiple large studies means the question is far from settled. For families already managing a dementia diagnosis or monitoring early cognitive changes, the prudent step is not to panic but to have a conversation with the prescribing physician about whether the PPI remains necessary.
Bone Fractures, Nutrient Deficiencies, and Infection Risk — The FDA’s Formal Warnings
The FDA has issued several specific safety communications about PPIs that go beyond the dementia debate. The agency warned of a 33 percent higher relative risk of fracture at any site among PPI users, with a 26 percent increase in hip fracture risk and a 58 percent increase in spine fracture risk. The mechanism involves interference with calcium absorption — suppress stomach acid long enough, and the body struggles to absorb the calcium it needs to maintain bone density. For older adults already at risk for osteoporosis, this compounds an existing vulnerability. The FDA also warned that PPIs may cause dangerously low magnesium levels (hypomagnesemia) when taken for longer than one year, and flagged a roughly 1.7-fold higher risk of Clostridioides difficile infection, a potentially life-threatening intestinal condition particularly dangerous in hospital and nursing home settings.
A 2025 umbrella review confirmed the PPI-C. difficile link, finding pooled odds ratios of 1.3 to 2.3 for C. difficile infection risk across populations. Beyond these FDA-flagged issues, long-term PPI use has also been associated with vitamin B12 deficiency, iron deficiency and anemia, community-acquired pneumonia, and observational associations with gastric cancer, colorectal cancer, and cardiovascular events. The tradeoff here is straightforward but rarely discussed with patients: a medication taken to manage discomfort from acid reflux may quietly increase the risk of a broken hip, a dangerous gut infection, or nutritional deficiencies that contribute to fatigue, cognitive fog, and frailty. None of these outcomes is guaranteed, but the cumulative probability across multiple risk categories adds up — particularly over years of continuous use.
Why Stopping PPIs Is Harder Than It Sounds
Even when patients and doctors agree that a PPI should be discontinued, quitting is not always simple. PPIs induce a condition called rebound acid hypersecretion, or RAHS. During long-term PPI use, the stomach responds to the suppression of acid by producing elevated levels of the hormone gastrin, which increases the stomach’s capacity to produce acid. When the PPI is suddenly stopped, all that pent-up acid-producing capacity surges back, often producing worse heartburn than the patient had before they started the medication. This rebound effect is not a sign that the patient truly needs the PPI.
It is a physiological withdrawal response. But patients who experience it naturally conclude that their acid reflux is severe and that they cannot live without the medication, creating a cycle of dependence. Successful deprescribing typically requires a gradual taper — reducing the dose over weeks, sometimes switching to an H2 blocker like famotidine as a bridge, and combining the taper with lifestyle modifications such as dietary changes, elevating the head of the bed, and avoiding late meals. A warning for caregivers: if an older adult with cognitive impairment has been on a PPI for years, abruptly stopping the medication without medical guidance could cause significant discomfort and confusion. The rebound symptoms can mimic a worsening medical condition, leading to unnecessary emergency visits or reinstatement of the drug. Any deprescribing effort should be coordinated with the prescribing physician and undertaken gradually.
The ICU-to-Medicine-Cabinet Pipeline
One pattern that frustrates gastroenterologists is what might be called the ICU-to-medicine-cabinet pipeline. In intensive care settings, off-label PPI use prevalence is as high as 55 percent, often prescribed for stress ulcer prophylaxis in critically ill patients. This is a legitimate short-term use.
The problem arises at discharge. Medications started in the hospital have a way of becoming permanent fixtures on a patient’s medication list, particularly when the patient sees multiple specialists and no single physician takes ownership of the complete regimen. The statistic bears repeating: 81 percent of patients started on PPIs during acute care continued them after transfer, though only 29 percent had appropriate indications. For older adults who cycle through hospitalizations, this is one of the most common pathways to unnecessary long-term PPI use.
Where the Evidence Is Heading
The medical community is not moving toward banning PPIs. These remain valuable medications for well-defined conditions. What is changing is the default assumption that PPIs are harmless enough to prescribe indefinitely without review.
The 2022 AGA/ACG guidelines calling for deprescribing trials represent a formal acknowledgment that the risk-benefit calculation shifts over time, particularly for patients who were started on PPIs for vague or temporary indications. As more data accumulates from randomized trials rather than observational studies alone, the dementia question in particular should become clearer. In the meantime, the practical takeaway is straightforward: every patient on a long-term PPI deserves a periodic conversation about whether it is still needed, and every caregiver should feel empowered to initiate that conversation.
Conclusion
Long-term PPI use has moved from a non-issue to a legitimate medical concern over the past decade. The evidence now points to elevated risks across multiple organ systems — kidneys, bones, the gut microbiome, and possibly the brain — with the added complication that these medications can be difficult to stop once started. For families navigating dementia care or monitoring cognitive health in aging loved ones, the PPI question deserves a place on the list of topics to discuss with a doctor, alongside the usual conversations about blood pressure, cholesterol, and fall prevention.
The most important step is also the simplest: ask the prescribing physician whether the PPI is still necessary. If the original indication was mild heartburn or a hospital stay that ended years ago, a supervised taper may be entirely appropriate. If a serious condition like Barrett’s esophagus or severe erosive GERD is confirmed, continued use may be justified — but even then, the lowest effective dose should be the goal. No medication should remain on autopilot indefinitely, least of all one with this many accumulating question marks.
Frequently Asked Questions
Are all antacids the same when it comes to these risks?
No. The concerns discussed here are specific to proton pump inhibitors — omeprazole (Prilosec), lansoprazole (Prevacid), esomeprazole (Nexium), and similar drugs. Over-the-counter antacids like Tums (calcium carbonate) and H2 blockers like famotidine (Pepcid) work differently and do not carry the same risk profile, though they have their own limitations for long-term use.
How long is too long to take a PPI?
The FDA recommends that OTC PPIs be limited to a 14-day course, up to three times per year. Prescription PPIs may be appropriate for longer durations under medical supervision for confirmed conditions like severe GERD or Barrett’s esophagus, but even these should be reviewed periodically.
Should I stop my PPI immediately if I am worried about dementia?
No. Abruptly stopping a PPI after long-term use can cause rebound acid hypersecretion, which may be worse than the original symptoms. Talk to your doctor about a gradual taper plan. The dementia link remains unproven as causal — the ASPREE randomized trial found no association — so a measured response is more appropriate than an abrupt one.
Can PPIs cause kidney damage even if I feel fine?
Yes. More than half of patients who develop chronic kidney damage while taking PPIs experience no acute kidney problems beforehand. Kidney function can silently deteriorate, which is why periodic lab work is important for anyone on long-term PPI therapy.
What should I ask my doctor about my PPI prescription?
Ask three questions: What was the original reason this was prescribed? Is that reason still present? And can we try a supervised taper to see if I still need it? If the answer to the second question is unclear, a deprescribing trial — as recommended by the AGA and ACG — is a reasonable next step.
